Table III.

Univariate and multivariate analyses of factors associated with the progression-free survival (all patients).

Variable	No. of patients	Univariate hazard ratio (95% CI)	P-value	Multivariate hazard ratio (95% CI)	P-value
Gender			0.0009		0.164
Male	119	1.626 (1.219–2.169)		1.333 (0.889–2.004)
Female	103	1		1
ECOG performance status			0.0278		0.629
3–4	20	1.754 (1.063–2.894)		1.635 (0.974–2.746)
0–2	202	1		1
Smoking history			0.0009		0.534
Current or former	100	1.639 (1.225–2.192)		1.142 (0.752–1.730)
Never	122	1		1
Histological type			0.1370
Non-adenocarcinoma	31	1.371 (0.904–2.079)
Adenocarcinoma	191	1
Prior gefitinib treatment			0.3890
No	131	1.135 (0.851–1.515)
Yes	91	1
Prior regimens			0.0364		0.867
>2	164	1.438 (1.023–2.020)		1.034 (0.701–1.529)
0–1	58	1		1
EGFR status			<0.0001		<0.001
Wild type or unknown	170	2.087 (1.548–2.814)		1.892 (1.346–2.662)
Mutation	52	1		1

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.